U.S. Viscosupplementation Market to Reach US$1,611.7 Mn by 2032 | Persistence Market Research

The U.S. viscosupplementation market has emerged as a critical component of the broader orthopedic and musculoskeletal care ecosystem, driven primarily by the growing burden of osteoarthritis (OA) and the rising demand for minimally invasive pain management solutions. Viscosupplementation involves the intra-articular injection of hyaluronic acid (HA) to restore the viscoelastic properties of synovial fluid in osteoarthritic joints, thereby reducing pain, improving mobility, and delaying surgical intervention. As OA continues to affect millions of adults in the United States-particularly those with knee involvement-viscosupplementation has become an established therapeutic option recommended by orthopedic specialists and rheumatologists alike. The increasing preference for outpatient-based, non-surgical interventions has further strengthened the role of viscosupplementation in routine OA management.

Download Your Free Sample & Explore Key Insights: https://www.persistencemarketresearch.com/samples/35654

From a market size perspective, the U.S. viscosupplementation market is projected to be valued at approximately US$1,127.6 million in 2025 and is expected to expand to US$1,611.7 million by 2032, registering a compound annual growth rate (CAGR) of 5.2% during the forecast period. This growth trajectory reflects both historical momentum and future potential, as the market recorded a CAGR of 4.4% between 2019 and 2024. Key growth drivers include the rising prevalence of knee osteoarthritis, technological advancements in HA formulations such as crosslinked and longer-lasting products, and increasing patient awareness regarding non-surgical treatment options.

Single-injection viscosupplementation has emerged as the leading product segment due to superior patient compliance and reduced clinical visits, while knee osteoarthritis remains the dominant application segment given its high incidence and functional impact. Geographically, the United States stands as the leading regional market globally, supported by favorable reimbursement frameworks, a strong outpatient care infrastructure, and high adoption of advanced orthopedic therapies.

Key Highlights from the Report

• The U.S. viscosupplementation market is expected to grow at a CAGR of 5.2% from 2025 to 2032.
• Single-injection hyaluronic acid products dominate the market due to improved convenience and compliance.
• Knee osteoarthritis accounts for the majority of viscosupplementation procedures nationwide.
• Rising prevalence of osteoarthritis among adults under 65 is expanding the patient pool.
• Technological innovations in crosslinked and long-acting HA formulations are enhancing treatment efficacy.
• Combination therapies integrating HA with regenerative agents present a significant future opportunity.

Market Segmentation Analysis

The U.S. viscosupplementation market is segmented based on product type, application, and end-user setting, each contributing uniquely to overall market dynamics. By product type, the market includes single-injection, three-injection, and five-injection viscosupplementation regimens. Among these, single-injection products command the largest market share due to their ability to deliver therapeutic benefits with fewer clinic visits, reduced patient discomfort, and improved adherence. Advances in HA crosslinking technology have enabled these single-dose formulations to maintain prolonged residence time within the joint, making them increasingly attractive to both clinicians and patients.

In terms of application, knee osteoarthritis represents the dominant segment, reflecting the high prevalence of knee involvement in OA patients. The knee joint is particularly susceptible to degenerative changes due to mechanical load and aging, resulting in pain, stiffness, and functional impairment.
Viscosupplementation offers targeted relief in knee OA by improving joint lubrication and shock absorption, which has positioned it as a preferred option before considering surgical interventions such as total knee replacement. Other applications, including hip, shoulder, and ankle OA, are being explored, but adoption remains limited due to anatomical complexity and variable clinical outcomes.

From an end-user perspective, hospitals, outpatient clinics, and ambulatory surgical centers constitute the primary settings for viscosupplementation procedures. Outpatient and ambulatory care centers are witnessing faster growth as healthcare systems prioritize cost efficiency, shorter recovery times, and reduced hospital burden. The minimally invasive nature of HA injections aligns well with these settings, supporting their expanding role in the market.

Get Custom Insights Designed for Your Business: https://www.persistencemarketresearch.com/request-customization/35654

Regional Insights and U.S. Market Trends

Within the United States, the viscosupplementation market demonstrates strong regional adoption driven by demographic trends, healthcare infrastructure, and reimbursement policies. States with a higher proportion of aging populations and elevated obesity rates tend to exhibit greater demand for OA treatments, including viscosupplementation. Urban centers with established orthopedic clinics and ambulatory care networks have become focal points for these procedures, reflecting improved patient access and specialist availability.

Research and innovation trends within the U.S. are also shaping the regional outlook. Ongoing clinical studies are evaluating combination therapies that integrate hyaluronic acid with platelet-rich plasma (PRP), anti-inflammatory drugs, or regenerative agents to enhance cartilage repair and extend therapeutic benefits. Additionally, the exploration of natural and synthetic polymers as drug delivery carriers or tissue-engineered scaffolds is expanding the potential applications of viscosupplementation beyond symptom management toward disease modification. Crosslinked HA formulations and biomaterial-based enhancements are expected to improve durability and patient outcomes, reinforcing the U.S. market's leadership in adoption and innovation.

Market Drivers

The primary driver of the U.S. viscosupplementation market is the increasing prevalence of osteoarthritis, particularly knee OA, among a growing and aging population. Osteoarthritis affects more than 32.5 million U.S. adults annually, with a significant proportion experiencing moderate to severe pain that limits daily activities. Lifestyle factors such as obesity, sedentary behavior, and joint injuries further exacerbate disease incidence. As OA imposes a substantial economic burden-estimated at US$136.8 billion annually in the U.S.-there is a strong incentive to adopt cost-effective, non-surgical interventions that delay or reduce the need for joint replacement surgeries.

Another critical driver is the growing preference for minimally invasive and outpatient-based treatments. Viscosupplementation injections are quick, safe, and require minimal recovery time, making them ideal for ambulatory care settings. Increasing support from Medicare and private insurers for outpatient procedures has improved reimbursement access, encouraging broader adoption. Technological advancements in HA formulations, including longer-lasting and more stable products, are further enhancing clinical confidence and expanding the therapeutic potential of viscosupplementation.

Market Restraints

Despite its benefits, the viscosupplementation market faces several restraints that may limit growth. The availability of alternative therapies such as corticosteroid injections, physical therapy, and emerging non-surgical interventions like genicular artery embolization presents significant competition. These alternatives are often perceived as more cost-effective or familiar within clinical practice, leading some physicians and patients to prioritize them over HA injections. Additionally, variability in clinical outcomes and mixed recommendations from professional guidelines have created uncertainty regarding the long-term efficacy of viscosupplementation.

Reimbursement challenges also act as a constraint, as coverage policies for viscosupplementation can vary across insurers and states. In some cases, limited reimbursement or prior authorization requirements discourage utilization, particularly in cost-sensitive healthcare settings. These factors collectively pose challenges to widespread adoption, especially among patient populations with limited access to specialty care.

Market Opportunities

The U.S. viscosupplementation market presents substantial opportunities driven by innovation and evolving treatment paradigms. One of the most promising areas is the development of combination therapies that integrate hyaluronic acid with regenerative or anti-inflammatory agents. Such approaches aim to address both symptom relief and underlying disease mechanisms, potentially improving long-term outcomes and expanding the eligible patient population.

Advancements in biomaterials and drug delivery technologies also offer new avenues for growth. The use of natural and synthetic polymers to enhance HA stability, prolong therapeutic effects, or deliver targeted therapies could significantly improve product differentiation and clinical value. Furthermore, increasing collaboration between manufacturers and outpatient care networks provides opportunities to strengthen distribution channels and establish viscosupplementation as a standard of care in non-hospital settings.

Checkout Now & Download Complete Market Report: https://www.persistencemarketresearch.com/checkout/35654

Company Insights

The U.S. viscosupplementation market is moderately competitive, characterized by the presence of established pharmaceutical and medical device companies with strong distribution capabilities and ongoing research initiatives. Key players operating in the market include:

• Sanofi S.A.
• Zimmer Biomet Holdings Inc.
• Bioventus LLC
• Anika Therapeutics Inc.
• Fidia Pharma USA Inc.
• Ferring B.V.
• Seikagaku Corporation
• OrthogenRx Inc. (Channel-Markers Medical)
• Medical Device Business Services, Inc. (Johnson & Johnson)
• AVNS
• Searchlight Pharma Inc.
• Aptissen GmbH
• Teva Pharmaceutical Industries Ltd.
• TRB Chemedica International SA
• IBSA Institut Biochimique SA

Market Segmentation

By Product

Single Injection Viscosupplementation
Three Injection Viscosupplementation
Five Injection Viscosupplementation

By Application

Knee Osteoarthritis
Shoulder Osteoarthritis
Hip Osteoarthritis
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region

U.S.

Recent developments highlight the market's innovation-driven nature. In April 2025, Seikagaku Corporation collaborated with Ono Pharmaceutical Co., Ltd. to co-develop and market the Gel-One intra-articular injection using proprietary crosslinking technology. Earlier, in April 2024, BioSenic announced positive phase 3 data for its single-injection JTA-004 therapy for knee osteoarthritis, demonstrating safety and efficacy at an international scientific forum.

Conclusion

The U.S. viscosupplementation market is positioned for steady and sustainable growth, supported by the rising prevalence of osteoarthritis, increasing demand for minimally invasive treatments, and continuous innovation in hyaluronic acid formulations. While competition from alternative therapies and reimbursement challenges persist, advancements in product technology and combination therapies are expanding the clinical relevance of viscosupplementation. With strong adoption in outpatient settings and a robust pipeline of innovative solutions, the market is expected to play an increasingly important role in osteoarthritis management, offering patients effective pain relief and improved quality of life while reducing the long-term burden on the healthcare system.

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.